RSPH 📈 Invesco S&P 500 Equal - Overview
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US46137V3327 • Health
RSPH: Pharmaceuticals, Biotechnology, Medical, Devices, Equipment, Services
The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index is composed of all of the components of the S&P 500® Health Care Index (the 'parent index'). The parent index is designed to measure the performance of common stocks of all companies included in the S&P 500® Index that are classified as members of the health care sector, as defined according to the Global Industry Classification Standard ('GICS®').
Additional Sources for RSPH ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
RSPH ETF Overview
| Market Cap in USD | 873m |
| Category | Health |
| TER | 0.40% |
| IPO / Inception | 2006-11-01 |
RSPH ETF Ratings
| Growth 5y | 47.7% |
| Fundamental | - |
| Dividend | 55.2% |
| Rel. Strength Industry | -104 |
| Analysts | - |
| Fair Price Momentum | 25.89 USD |
| Fair Price DCF | - |
RSPH Dividends
| Dividend Yield 12m | 0.52% |
| Yield on Cost 5y | 0.70% |
| Annual Growth 5y | 10.72% |
| Payout Consistency | 95.7% |
RSPH Growth Ratios
| Growth Correlation 3m | -78.6% |
| Growth Correlation 12m | 40% |
| Growth Correlation 5y | 74% |
| CAGR 5y | 6.39% |
| CAGR/Mean DD 5y | 1.00 |
| Sharpe Ratio 12m | -0.31 |
| Alpha | -23.32 |
| Beta | 0.87 |
| Volatility | 14.79% |
| Current Volume | 106.8k |
| Average Volume 20d | 86.5k |
What is the price of RSPH stocks?
As of December 22, 2024, the stock is trading at USD 29.44 with a total of 106,770 shares traded.
Over the past week, the price has changed by -4.29%, over one month by -3.33%, over three months by -10.67% and over the past year by -0.95%.
As of December 22, 2024, the stock is trading at USD 29.44 with a total of 106,770 shares traded.
Over the past week, the price has changed by -4.29%, over one month by -3.33%, over three months by -10.67% and over the past year by -0.95%.
Is Invesco S&P 500 Equal a good stock to buy?
Partly, yes. Based on ValueRay Analyses, Invesco S&P 500 Equal (NYSE ARCA:RSPH) is currently (December 2024) ok to buy, but has to be watched. It has a Growth Technical Rating of 47.74 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RSPH as of December 2024 is 25.89. This means that RSPH is currently overvalued and has a potential downside of -12.06%.
Partly, yes. Based on ValueRay Analyses, Invesco S&P 500 Equal (NYSE ARCA:RSPH) is currently (December 2024) ok to buy, but has to be watched. It has a Growth Technical Rating of 47.74 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RSPH as of December 2024 is 25.89. This means that RSPH is currently overvalued and has a potential downside of -12.06%.
Is RSPH a buy, sell or hold?
Invesco S&P 500 Equal has no consensus analysts rating.
Invesco S&P 500 Equal has no consensus analysts rating.
What are the forecast for RSPH stock price target?
According to ValueRays Forecast Model, RSPH Invesco S&P 500 Equal will be worth about 28.7 in December 2025. The stock is currently trading at 29.44. This means that the stock has a potential downside of -2.62%.
According to ValueRays Forecast Model, RSPH Invesco S&P 500 Equal will be worth about 28.7 in December 2025. The stock is currently trading at 29.44. This means that the stock has a potential downside of -2.62%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 28.7 | -2.6% |